Q2 2026 saw 16% sales growth and record gross margins, driven by the My Medic acquisition and strong core business performance. Investments in automation and new product lines support long-term growth, while risks from tariffs and inflation persist.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.